1024 - Real-world Adherence and Persistence with Long-Acting Cabotegravir Plus Rilpivirine (CAB+RPV LA) Compared to Oral Antiretroviral Therapy (ART) Among People with HIV (PWH) in the US: The ABOVE Study

Presenting Author(s)

• 

  Cindy Garris, MS (she/her/hers)

  Senior Director, US Health Outcomes
  ViiV Healthcare
  Durham, NC, United States

  Slides

Co-Author(s)

• RD

  Raj Desai, PhD

  Analysis Group, Inc.
  Boston, Massachusetts, United States
• RC

  Rose Chang, ScD

  Analysis Group, Inc.
  Boston, Massachusetts, United States
• LC

  Louise Clear, MPH

  Analysis Group, Inc.
  Boston, Massachusetts, United States
• ZC

  Zhuo Chen, MPH

  Analysis Group, Inc.
  Boston, Massachusetts, United States
• DL

  Daisy Liu, MS

  Analysis Group, Inc.
  Boston, Massachusetts, United States
• MD

  Maral DerSarkissian, PhD

  Manager
  Analysis Group, Inc.
  Los Angeles, CA, United States
• 

  Paula Teichner, PharmD

  Medical Director
  ViiV Healthcare
  Chicago, Illinois, United States
• EO

  Edgar T. Overton, MD

  ViiV Healthcare
  Durham, North Carolina, United States